-
Global Biotechnology & Pharmaceutical Markets4 weeks agoNovo’s Investigational Obesity and Diabetes Drug CagriSema Reduces ‘Food Noise’ and Shows Benefits in Organ and Bone Health
Bagsværd, Denmark, 30 September 2026 – Novo Nordisk today announced new data on how CagriSema works inside both the brain and body, presented at the European...
-
Global Biotechnology & Pharmaceutical Markets4 weeks agoSTAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial
An investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high discontinuation rates raise questions about tolerability.
-
Global Biotechnology & Pharmaceutical Markets4 weeks agoLilly builds commercial case for GLP-1 products over Novo with indirect analyses
Eli Lilly’s weight loss pill Foundayo has had a “slower-than-hoped” launch, according to BMO Capital Markets, which contended that the indirect comparison data—despite falling short of...
-
Global Biotechnology & Pharmaceutical Markets4 weeks agoOpinion: America’s biotech race with China must be won at home
“The surest way to secure our biotech lead is to build up our own capabilities,” write Gary Locke and Patrick McHenry.
-
Global Biotechnology & Pharmaceutical Markets4 weeks agoFDA Investigation Leads to Charges Against Two Indian Nationals Involved in Transnational Counterfeit Drug Distribution Scheme
The U.S. Attorney’s Office for the Middle District of Florida and the Criminal Division of the U.S. Department of Justice today announced federal charges against Swapnadip...
-
Global Biotechnology & Pharmaceutical Markets4 weeks agoSTAT+: Lawmakers urge Trump to rethink new rule that could restrict imported meds from Canada and overseas
Some lawmakers are urging the Trump administration to rethink a pending rule that may prevent Americans from obtaining medicines from licensed international pharmacies.
-
Global Biotechnology & Pharmaceutical Markets4 weeks agoSTAT+: PhRMA taps Eric Cantor as new CEO
Eric Cantor, a former GOP House majority leader, is taking the helm of PhRMA at a challenging time for the industry.
-
Global Biotechnology & Pharmaceutical Markets4 weeks agoNovo turns to Hengrui for another oral obesity drug
Novo has agreed to pay up to $2.6 billion for rights to a weight-loss pill, developed by China's Hengrui Pharma, that could be dosed just once...
-
Global Biotechnology & Pharmaceutical Markets4 weeks agoTolerance Bio signs $560m worldwide TLB-33 deal with Tanabe Pharma
The agreement grants Tolerance Bio exclusive commercialisation rights outside Japan, whilst Tanabe Pharma retains marketing rights within Japan. The terms also include equity consideration and tiered...
-
Global Biotechnology & Pharmaceutical Markets1 month ago3 steps for taking on Novartis in radiopharma: Curium up first
To successfully challenge Novartis on two planned fronts, Curium will need to overcome the unique challenges posed by radiopharmaceutical supply to get products to patients and...
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
